WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

(11) International Publication Number:

WO 00/12485

C07D 239/48, A61K 31/505

A1

(43) International Publication Date:

9 March 2000 (09.03.00)

(21) International Application Number:

PCT/GB99/02790

(22) International Filing Date:

24 August 1999 (24.08.99)

(30) Priority Data:

9818989.7 9828433.4 29 August 1998 (29.08.98) GB GB

24 December 1998 (24.12.98)

(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): BREAULT, Gloria, Anne [US/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB), PEASE, Janet, Elizabeth [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (74) Agent: MACK, John, Richard; AstraZeneca PLC, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG. BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB. GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG. KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH. GM. KE. LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD. RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK. ES, FI, FR, GB, GR. IE. IT. LU, MC, NL, PT, SE), OAPI patent (BF. BJ. CF. CG. CI. CM, GA, GN, GW, ML, MR. NE, SN, TD, TG).

Published

With international search report.

(54) Title: PYRIMIDINE COMPOUNDS

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

(1)

$$X \sim (CH_2)n \longrightarrow (CH_2)m \longrightarrow Z$$
 (la)

(57) Abstract

A pyrimidine derivative of formula (I) wherein, for example, R1 is hydrogen, (1-6C)alkyl, (3-5C)alkenyl or (3-5C)alkynyl; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q1 and Q2 bears on any available carbon atom one substituent of formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the -NH- link]; wherein, for example, X is CH2, O, S or NH; Y is H or as defined for Z; Z is OH, SH, NH2, (1-4C)alkoxy, (1-4C)alkylthio, -NH(1-4C)alkyl, -N[(1-4C)alkyl]₂ or -NH-(3-8C)cycloalkyl; n is 1, 2 or 3; m is 1, 2 or 3; and Q₁ and Q₂ may optionally bear other substituents selected, for example, from halogeno, (1-6C)alkyl, cyano and (2-4C)alkenyl; or a pharmaceutically-acceptable salt or in-vivo-hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described.